Company intelligence / Profile preview

YYB

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

YYB Therapeutics is a South Korean clinical-stage biotechnology company focused on developing innovative antibody-based therapeutics for cancer and other refractory diseases. The company's lead candidate, YYB-101, is a first-in-class humanized neutralizing antibody targeting Hepatocyte Growth Factor (HGF), currently being evaluated in Phase 2 clinical trials for solid tumors including colorectal cancer and glioblastoma. YYB Therapeutics also maintains a pipeline of multi-specific antibodies and treatments for ophthalmic conditions like age-related macular degeneration. By leveraging its expertise in antibody engineering, the company aims to address high unmet medical needs through targeted biologics.

Therapeutic areas: OncologyOphthalmology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody
Industry: Biotech

Partnerships

YooYoung Pharmaceutical

Beyond the preview

Go deeper on YYB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YYB.

Explore the full profile